Table 1 Demographics and responses of... | American Society of Hematology

Table 1

Demographics and responses of patients who received ibrutinib before CAR T-cell therapy

Subject UPN	Age, y/sex	Previous therapies	CLL tumor characteristics	Ibrutinib status during T-cell collection	CLL involvement at CTL019 infusion	Response to CTL019
18	61/male	Fludarabine/cyclophosphamide/rituximab × 6 cycles Bendamustine/rituximab × 1 cycle Oxaliplatin/fludarabine/cytarabine/rituximab × 2 cycles Selinexor × 1 cycle Ibrutinib × 12 mo	trisomy 12; del12q14; del11q; del17p	Discontinued 2 mo before T-cell collection	Cytopenias; BM 20% involved with CLL; bulky diffuse adenopathy	Marked PR; cytopenias resolved at 2 mo; BM minimally involved; >50% decrease in adenopathy; relapsed with CD19-negative disease
29	68/male	Rituximab/fludarabine × 6 cycles Ofatumumab × 2 cycles Bendamustine/ofatumumab × 1 cycle Ibrutinib × 15 mo	13qdel; trisomy 21; 17pdel	Discontinued 11 d before T-cell collection	Blood involved; BM 25% involved with CLL; diffuse adenopathy	PR: cleared blood and BM at day 28; persistent adenopathy
47	57/male	Fludarabine/cyclophosphamide/rituximab × 3 cycles Bendamustine × 1 cycle Ibrutinib × 16 mo	p53del	Ongoing at T-cell collection*; discontinued 7 d before CTL019 treatment, per protocol	Normal ALC; BM 70% involved with CLL; diffuse adenopathy	CR: cleared blood and BM at day 28; no adenopathy

Subject UPN	Age, y/sex	Previous therapies	CLL tumor characteristics	Ibrutinib status during T-cell collection	CLL involvement at CTL019 infusion	Response to CTL019
18	61/male	Fludarabine/cyclophosphamide/rituximab × 6 cycles Bendamustine/rituximab × 1 cycle Oxaliplatin/fludarabine/cytarabine/rituximab × 2 cycles Selinexor × 1 cycle Ibrutinib × 12 mo	trisomy 12; del12q14; del11q; del17p	Discontinued 2 mo before T-cell collection	Cytopenias; BM 20% involved with CLL; bulky diffuse adenopathy	Marked PR; cytopenias resolved at 2 mo; BM minimally involved; >50% decrease in adenopathy; relapsed with CD19-negative disease
29	68/male	Rituximab/fludarabine × 6 cycles Ofatumumab × 2 cycles Bendamustine/ofatumumab × 1 cycle Ibrutinib × 15 mo	13qdel; trisomy 21; 17pdel	Discontinued 11 d before T-cell collection	Blood involved; BM 25% involved with CLL; diffuse adenopathy	PR: cleared blood and BM at day 28; persistent adenopathy
47	57/male	Fludarabine/cyclophosphamide/rituximab × 3 cycles Bendamustine × 1 cycle Ibrutinib × 16 mo	p53del	Ongoing at T-cell collection*; discontinued 7 d before CTL019 treatment, per protocol	Normal ALC; BM 70% involved with CLL; diffuse adenopathy	CR: cleared blood and BM at day 28; no adenopathy

ALC, absolute lymphocyte count; BM, bone marrow; PR, partial response; UPN, unique patient number.

Modified CTL019 manufacturing process.

Absolute lymphocyte count.